Peers of AbbVie Inc (ABBV)
Health Care · Biotechnology
Stock price divided by trailing twelve-month (TTM) GAAP earnings per share. Shows how much investors pay for each dollar of recent profit.
Latest P/E Ratio
74.23x
As of Sep 29, 2026
Beyond P/E Ratio, the valuation view includes forward multiples, EV ratios, cash flow yields, and multi-year chart history for further research.
| Date | P/E Ratio |
|---|---|
| Sep 29, 2026 | 74.23x |
| Sep 28, 2026 | 75.07x |
| Sep 25, 2026 | 74.52x |
| Sep 24, 2026 | 74.74x |
| Sep 23, 2026 | 74.73x |
| Sep 22, 2026 | 74.77x |
| Sep 21, 2026 | 74.56x |
| Sep 18, 2026 | 74.42x |
P/E Ratio = Current Stock Price ÷ Trailing 12-Month (TTM) Diluted EPS (or Market Cap ÷ TTM Net Income). Chartloom divides stock price by trailing twelve-month EPS, calculated by dividing TTM net income by the weighted-average share count from filings. Note: Variations in share-count conventions across data providers may cause slight differences in reported P/E multiples.
Trailing P/E is based on reported GAAP results and is one of the most widely used valuation metrics.
Read the general P/E Ratio definition, formula, and analyst usage guide.
P/E Ratio guideInformational research only; not personalized advice. Values reflect the latest available data on Chartloom and may differ from other sources.
